In this review, we will outline dimensions in which outcome of patients with myelofibrosis
undergoing curative treatment can be optimized: patient selection, transplant procedure, and …

Introduction Ruxolitinib is the first approved drug for treatment of myelofibrosis, but its impact
of outcome after allogeneic stem cell transplantation (ASCT) is unknown. Patients and …

Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …

Myelofibrosis is one of the Philadelphia chromosome (Ph)-negative myeloproliferative
neoplasms with heterogeneous clinical course. Though many treatment options, including …

Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the
cornerstone of curative approach to myelofibrosis (MF), although it is burdened by not …

In this SFGM-TC registry study, we report the results after stem cell transplantation (HSCT) in
305 myelofibrosis patients, in order to determine potential risk factors associated with …

Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate
and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction …

Up to now allo-HSCT is the only curative treatment for patients with myelofibrosis
(MF)(Ballen, et al, Guardiola, et al 1999, Kroger, et al 2007, Robin, et al 2011). The …

INTRODUCTION Allogeneic stem cell transplant (ASCT) is currently the only curative
therapy for myelofibrosis (MF). Ruxolitinib, an inhibitor of the JAK-STAT pathway, has been …

Haploidentical stem cell transplantation is a viable strategy in the absence of an HLA-
identical donor, but in myelofibrosis (MF), concerns may rise due to the risk of graft failure …